Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvogen is first with Revlimid rival in EU

Executive Summary

Alvogen is claiming the first approvals in “several European countries” for its generic version of Celgene’s Revlimid (lenalidomide) capsules, after its Lotus Pharmaceuticals affiliate “successfully concluded multiple registration procedures” for the oncology drug. Lotus’ lenalidomide has been approved in European markets in seven strengths: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg capsules.

You may also be interested in...



Lenalidomide Launch Kicks Off A Year Of Revlimid Competition

Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.

Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition

Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.

Alvogen Claims Lead On Lenalidomide In Europe

Alvogen is claiming the first European launch of a generic rival to Revlimid, rolling out the oncology drug in several central and eastern European markets. Meanwhile, IPR challenges to three Revlimid patents in the US have been denied.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB000720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel